Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
US Department of Justice
Federal Trade Commission
Covington
Daiichi Sankyo
Cerilliant
Express Scripts
QuintilesIMS
Mallinckrodt

Generated: January 16, 2019

DrugPatentWatch Database Preview

J And J Company Profile

« Back to Dashboard

Summary for J And J
International Patents:103
US Patents:8
Tradenames:25
Ingredients:12
NDAs:32

Drugs and US Patents for J And J

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc IMODIUM loperamide hydrochloride CAPSULE;ORAL 017690-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
J And J Consumer Inc CHILDREN'S ZYRTEC ALLERGY cetirizine hydrochloride SYRUP;ORAL 022155-002 Nov 16, 2007 OTC Yes Yes ➤ Sign Up ➤ Sign Up
J And J Consumer Inc ZYRTEC HIVES RELIEF cetirizine hydrochloride TABLET;ORAL 019835-005 Nov 16, 2007 DISCN Yes No ➤ Sign Up ➤ Sign Up
J And J Consumer Inc IMODIUM A-D loperamide hydrochloride SOLUTION;ORAL 019487-001 Mar 1, 1988 OTC Yes Yes ➤ Sign Up ➤ Sign Up
J And J Consumer Inc ZYRTEC ALLERGY cetirizine hydrochloride TABLET;ORAL 019835-003 Nov 16, 2007 DISCN Yes No ➤ Sign Up ➤ Sign Up
J And J Consumer Inc IBUPROFEN ibuprofen TABLET;ORAL 070081-001 Jun 16, 1986 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for J And J

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
J And J Consumer Inc TYLENOL acetaminophen TABLET, EXTENDED RELEASE;ORAL 019872-001 Jun 8, 1994 4,820,522 ➤ Sign Up
J And J Consumer Inc ZYRTEC cetirizine hydrochloride SYRUP;ORAL 020346-001 Sep 27, 1996 4,525,358*PED ➤ Sign Up
J And J Consumer Inc IMODIUM A-D EZ CHEWS loperamide hydrochloride TABLET, CHEWABLE;ORAL 020448-001 Jul 24, 1997 5,489,436 ➤ Sign Up
J And J Consumer Inc PEPCID AC famotidine TABLET, CHEWABLE;ORAL 020801-001 Sep 24, 1998 5,075,114*PED ➤ Sign Up
J And J Consumer Inc IMODIUM loperamide hydrochloride CAPSULE;ORAL 017694-001 Approved Prior to Jan 1, 1982 3,714,159 ➤ Sign Up
J And J Consumer Inc PEPCID AC famotidine TABLET, CHEWABLE;ORAL 020801-002 Dec 17, 2007 5,075,114*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for J AND J drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Chewable Tablets 5 mg and 10 mg ➤ Subscribe 2005-03-25
➤ Subscribe Syrup 5 mg/5 mL ➤ Subscribe 2007-03-19
➤ Subscribe Chewable Tablets 800 mg/ 10 mg/ 165 mg (OTC) ➤ Subscribe 2004-11-01

Supplementary Protection Certificates for J And J Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008006,C0933372 Lithuania ➤ Sign Up PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
0689 Netherlands ➤ Sign Up PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912
C/GB03/033 United Kingdom ➤ Sign Up PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
C/GB08/005 United Kingdom ➤ Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
C/GB98/013 United Kingdom ➤ Sign Up PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923
2014 00050 Denmark ➤ Sign Up PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Argus Health
Farmers Insurance
Federal Trade Commission
Express Scripts
Merck
Daiichi Sankyo
Citi
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.